Meningioma - A Pipeline Analysis Report

Overview of the drug development for meningioma

Meningioma is a tumor that arises from the meninges, membranes that surround the brain and the spinal cord. Although it is no exactly a brain tumor, it is included in this category because it may compress or squeeze the adjacent brain tissues, nerves, and vessels. It is most common type of tumor that forms in the head. Most meningiomas grow very slowly, often over many years, without causing symptoms. But in some cases, their effects on the adjacent brain tissues, nerves, or vessels may cause serious consequences. Since most of the meningiomas grow slowly, they do not always require immediate treatment and can be monitored over time.  The number of cancer registries worldwide that recorded malignant brain tumors is less, and there are concerns regarding the accuracy of the recorded data. A surge in the incidences of primary brain tumors in general and of meningiomas specifically has been registered in many countries during the past decades. It is said that the main reasons for this surge could be the aging population, better access to advanced healthcare facilities and diagnostic procedures, and the changes in coding classification for the meningiomas registered. As a result, the increasing number of instances of the disease have further boosted the drug development for meningioma.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for meningioma. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of meningioma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• AstraZeneca
• Eli Lilly
• Merck Sharp & Dohme
• Novartis
• Pfizer

Therapeutic assessment of the drug development for meningioma by route of administration

• Oral
• Intravenous
• Intramuscular

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for meningioma by targets

• PD-1
• CDK4 and CDK6
• mTORC1/mTORC2
• MEK1/MEK2
• RTK
• NMDA receptor
• PP2A
• DNA
• PDL1
• Somatostatin receptor

According to this pipeline analysis report, most of the molecules that are currently in the drug development for meningioma are being developed on PD-1 targets and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for meningioma?
• What are the companies that are currently involved in the development of drug molecules for meningioma?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.